FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wim ten Bokkel Huinink

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
David Boss; Wandena S Siegel-Lakhai; Nadja E van Egmond-Schoemaker; Dick Pluim; Hilde Rosing; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Wim W ten Bokkel Huinink; Jozef Sufliarsky; Willem M Smit; Stanislav Spanik; Maria Wagnerova; Hal W Hirte; Stan Kaye; Anandhi R Johri; Amit Oza
Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
H H Helgason; C M F Kruijtzer; Alwin D R Huitema; S G Marcus; Wim W ten Bokkel Huinink; Margaret Schot; Jan H Schornagel; Jos H Beijnen; J H M Schellens
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wim ten Bokkel Huinink (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: David Boss; Wandena S Siegel-Lakhai; Nadja E van Egmond-Schoemaker; Dick Pluim; Hilde Rosing; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4475-83.
2009: Wim W ten Bokkel Huinink; Jozef Sufliarsky; Willem M Smit; Stanislav Spanik; Maria Wagnerova; Hal W Hirte; Stan Kaye; Anandhi R Johri; Amit Oza
Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3097-103.
2006: H H Helgason; C M F Kruijtzer; Alwin D R Huitema; S G Marcus; Wim W ten Bokkel Huinink; Margaret Schot; Jan H Schornagel; Jos H Beijnen; J H M Schellens
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2006;95(7):794-800.
2006: Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):467-75.
2005: Daniel W Rea; J W R Nortier; Wim W ten Bokkel Huinink; SJ Falk; D J Richel; Timothy S Maughan; Gerard Groenewegen; JM Smit; Neil M Steven; J M Bakker; D Semiond; David J Kerr; Cornelis J A Punt
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1123-32.
2004: Nadja E Schoemaker; Isa E L M Kuppens; Vladimir M Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; Rune Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; Kjell Magne Tveit; A Garin; G Gruia; A Mourier; D Sibaud; Patricia Lefebvre; Jos H Beijnen; J H M Schellens; Wim W ten Bokkel Huinink
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
British journal of cancer 2004;91(8):1434-41.
2004: Thomas Kerbusch; Gerard Groenewegen; Ron A A Mathôt; Virginie M M Herben; Wim W ten Bokkel Huinink; M Swart; B Ambaum; Hilde Rosing; Sindy Jansen; Emile E Voest; Jos H Beijnen; J H M Schellens
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
British journal of cancer 2004;90(12):2268-77.
2004: Wim W ten Bokkel Huinink; SR Lane; GA Ross
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(1):100-3.
2002: Nadja E Schoemaker; Charlotte van Kesteren; Hilde Rosing; Sindy Jansen; M Swart; J Lieverst; Daniela Fraier; Massimo Breda; Cinzia Pellizzoni; Riccardo Spinelli; M Grazia Porro; Jos H Beijnen; J H M Schellens; Wim W ten Bokkel Huinink
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
British journal of cancer 2002;87(6):608-14.
2002: Renato A Valdés Olmos; Ignasi Carrió; Cornelis A Hoefnagel; Montserrat Estorch; Wim W ten Bokkel Huinink; J López-Pousa; Otilia Dalesio
High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction.
Nuclear medicine communications 2002;23(9):871-7.
2002: Mirjam Crul; Hilde Rosing; GJ de Klerk; Ria Dubbelman; M Traiser; S Reichert; N G Knebel; J H M Schellens; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1615-21.
2002: Virginie M M Herben; nadja E Schoemaker; Hilde Rosing; Desiree M van Zomeren; Wim W ten Bokkel Huinink; Ria Dubbelman; Solange Hearn; Jan H M Schellens; Jos H Beijnen
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Cancer chemotherapy and pharmacology 2002;50(1):59-64.
2002: C M F Kruijtzer; Jos H Beijnen; Hilde Rosing; Wim W ten Bokkel Huinink; Margaret Schot; Roxanne C Jewell; Elaine M Paul; J H M Schellens
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2943-50.
2002: Jetske M Meerum Terwogt; Gerard Groenewegen; Dick Pluim; Marc Maliepaard; Matthijs M Tibben; Albert Huisman; Wim W ten Bokkel Huinink; Margaret Schot; Helen Welbank; Emile E Voest; Jos H Beijnen; Jan M Schellens
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Cancer chemotherapy and pharmacology 2002;49(3):201-10.
2002: Nadja E Schoemaker; Virginie M M Herben; Laurina A de Jong; Robert C A M van Waardenburg; Dick Pluim; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
Anti-cancer drugs 2002;13(1):87-91.
2001: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Mariët Ouwehand; Heleen A Bardelmeijer; Hilde Rosing; FJ Koopman; Margaret Schot; Wim W ten Bokkel Huinink; Jos H Beijnen
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Mirte M Malingré; Wim W ten Bokkel Huinink; K Duchin; J H M Schellens; Jos H Beijnen
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Anti-cancer drugs 2001;12(7):591-3.
2001: Mirte M Malingré; Wim W ten Bokkel Huinink; M Mackay; J H M Schellens; Jos H Beijnen
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
European journal of clinical pharmacology 2001;57(4):305-7.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: Jetske M Meerum Terwogt; Wim W ten Bokkel Huinink; J H M Schellens; Margaret Schot; IA Mandjes; M G Zurlo; M Rocchetti; Hilde Rosing; FJ Koopman; Jos H Beijnen
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Anti-cancer drugs 2001;12(4):315-23.
2001: M Gore; Wim W ten Bokkel Huinink; J Carmichael; A Gordon; N Davidson; R Coleman; M Spaczynski; J F Héron; Giorgio Bolis; H Malmström; John Malfetano; C Scarabelli; P Vennin; G Ross; Scott Z Fields
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):1893-900.
2001: Mirte M Malingré; Dick J Richel; Jos H Beijnen; Hilde Rosing; FJ Koopman; Wim W ten Bokkel Huinink; Margaret Schot; J H M Schellens
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1160-6.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Roxanne C Jewell; Elaine M Paul; Wim W ten Bokkel Huinink; J H M Schellens
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
British journal of cancer 2001;84(1):42-7.
2000: Nine van der Vange; A R van Goethem; Frans A N Zoetmulder; MM Kaag; Paul van de Vaart; Wim W ten Bokkel Huinink; Jos H Beijnen
Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2000;26(7):663-8.
2000: Jetske M Meerum Terwogt; Olaf van Tellingen; VR Nannan Panday; manon huizing; J H M Schellens; Wim W ten Bokkel Huinink; M U Boschma; Giuseppe Giaccone; Cindy Veenhof; Jos H Beijnen
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Jaap Verweij; J H M Schellens; Jos H Beijnen; L Pronk; M Bo; V Lustig; H van Tinteren; M Mackay; Wim W ten Bokkel Huinink
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Anti-cancer drugs 2000;11(4):249-55.
2000: Hilde Rosing; V Lustig; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Sjoerd Rodenhuis; A Bult; Jos H Beijnen
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Cancer chemotherapy and pharmacology 2000;45(3):213-8.
1999: Jetske M Meerum Terwogt; Mirte M Malingré; Jos H Beijnen; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Olaf van Tellingen; M Swart; J H M Schellens
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
Journal of cancer research and clinical oncology 1999;125(11):615-20.
1999: Virginie M M Herben; Hilde Rosing; Wim W ten Bokkel Huinink; Desiree M van Zomeren; Diane Batchelor; E Doyle; F D Beusenberg; Jos H Beijnen; J H M Schellens
Oral topotecan: bioavailablity and effect of food co-administration.
British journal of cancer 1999;80(9):1380-6.
1999: VR Panday; Wim W ten Bokkel Huinink; Jan B Vermorken; Hilde Rosing; FJ Koopman; M Swart; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: Virginie M M Herben; R van Gijn; J H M Schellens; Margaret Schot; J Lieverst; Michel J X Hillebrand; Nadja E Schoemaker; M G Porro; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1906-14.
1999: Virginie M M Herben; J H M Schellens; M Swart; G Gruia; L Vernillet; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1897-905.
1999: JM Terwogt; IA Mandjes; H Sindermann; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
British journal of cancer 1999;79(7-8):1158-61.
1999: Virginie M M Herben; VR Panday; Dick J Richel; J H M Schellens; Nine van der Vange; Hilde Rosing; F D Beusenberg; Solange Hearn; E Doyle; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):747-55.
1999: VR Nannan Panday; Ronald de Wit; Jan H Schornagel; Margaret Schot; Hilde Rosing; J Lieverst; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 1999;44(4):349-53.
1999: Hilde Rosing; Wim W ten Bokkel Huinink; R van Gijn; R F Rombouts; Auke Bult; Jos H Beijnen
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).
European journal of drug metabolism and pharmacokinetics 1999;24(1):69-77.
1999: R van Gijn; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; Jan B Vermorken; Olaf van Tellingen; Hilde Rosing; LJ van Warmerdam; Jos H Beijnen
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1998: VR Panday; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Michel J X Hillebrand; Ria Dubbelman; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: Wim W ten Bokkel Huinink; C A de Swart; D W van Toorn; G Morack; WP Breed; H F Hillen; J J van der Hoeven; N S Reed; D J Fairlamb; S Y Chan; K A Godfrey; Gunnar Kristensen; H van Tinteren; B Ehmer
Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy.
Medical oncology (Northwood, London, England) 1998;15(3):174-82.
1998: R van Gijn; Virginie M M Herben; Michel J X Hillebrand; Wim W ten Bokkel Huinink; Auke Bult; Jos H Beijnen
High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.
Journal of pharmaceutical and biomedical analysis 1998;17(8):1257-65.
1998: Virginie M M Herben; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Pharmacy world & science : PWS 1998;20(4):161-72.
1998: Virginie M M Herben; Wim W ten Bokkel Huinink; Margaret Schot; IR Hudson; Jos H Beijnen
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Anti-cancer drugs 1998;9(5):411-8.
1998: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; Jan B Vermorken; Giuseppe Giaccone; Cindy Veenhof; J H M Schellens; Jos H Beijnen
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: Paul van de Vaart; Nine van der Vange; Frans A N Zoetmulder; A R van Goethem; Olaf van Tellingen; Wim W ten Bokkel Huinink; Jos H Beijnen; Harry Bartelink; Adrian C Begg
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(1):148-54.
1997: Hilde Rosing; V Lustig; F P Koopman; Wim W ten Bokkel Huinink; Jos H Beijnen
Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(1):89-98.
1997: Wim W ten Bokkel Huinink; V Lustig; Ria Dubbelman; A Hiemstra; Sjoerd Rodenhuis
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S23-5.
1997: VR Panday; manon huizing; P H Willemse; A De Graeff; Wim W ten Bokkel Huinink; Jan B Vermorken; Jos H Beijnen
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Seminars in oncology 1997;24(4 Suppl 11):S11-34-S11-38.
1997: Wim W ten Bokkel Huinink; M Gore; J Carmichael; A Gordon; John Malfetano; IR Hudson; C Broom; C Scarabelli; N Davidson; M Spanczynski; Giorgio Bolis; H Malmström; R Coleman; S C Fields; J F Heron
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2183-93.
1997: S Gwyther; Giorgio Bolis; M Gore; Wim W ten Bokkel Huinink; Jaap Verweij; IR Hudson; R Despax; A Jiménez-Lacave
Experience with independent radiological review during a topotecan trial in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(5):463-8.
1997: manon huizing; LJ van Warmerdam; Hilde Rosing; M C Schaefers; A Lai; TJ Helmerhorst; Cindy Veenhof; M J Birkhofer; Sjoerd Rodenhuis; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1953-64.
1997: Wim W ten Bokkel Huinink; LJ van Warmerdam; TJ Helmerhorst; M C Schaefers; Jos H Beijnen; Sjoerd Rodenhuis
Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(4):351-4.
1997: J D Jonkman-de Vries; B J Van den Bemt; Wim W ten Bokkel Huinink; Willy J M Underberg; J Jantina Kettenes-van den Bosch; RE Henrar; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.
PDA journal of pharmaceutical science and technology / PDA 1997;51(2):89-95.
1997: Wim W ten Bokkel Huinink; J Carmichael; Deborah K Armstrong; A Gordon; John Malfetano
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
Seminars in oncology 1997;24(1 Suppl 5):S5-19-S5-25.
1997: LJ van Warmerdam; manon huizing; G Giaccone; P E Postmus; Wim W ten Bokkel Huinink; nico van zandwijk; M G Koolen; TJ Helmerhorst; W J van der Vijgh; Cindy Veenhof; Jos H Beijnen
Clinical pharmacology of carboplatin administered in combination with paclitaxel.
Seminars in oncology 1997;24(1 Suppl 2):S2-97-S2-104.
1997: Wim W ten Bokkel Huinink; Cindy Veenhof; manon huizing; Sjoerd Rodenhuis; TJ Helmerhorst; Ria Dubbelman; Otilia Dalesio; Jos H Beijnen; B Winograd
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
Seminars in oncology 1997;24(1 Suppl 2):S2-31-S2-33.
1997: Virginie M M Herben; Wim W ten Bokkel Huinink; A C Dubbelman; IA Mandjes; Y Groot; D M van Gortel-van Zomeren; Jos H Beijnen
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
British journal of cancer 1997;76(11):1500-8.
1997: Wim W ten Bokkel Huinink
Anticancer drug evaluation: continuing progress from existing methodology.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 2():S8-10.
1997: Hilde Rosing; Virginie M M Herben; D M van Gortel-van Zomeren; E Hop; J Jantina Kettenes-van den Bosch; Wim W ten Bokkel Huinink; Jos H Beijnen
Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.
Cancer chemotherapy and pharmacology 1997;39(6):498-504.
1997: R de Wit; R Sylvester; C Tsitsa; P H M De Mulder; D T Sleyfer; Wim W ten Bokkel Huinink; Stanley B Kaye; A T van Oosterom; E Boven; K Vermeylen; Gerrit Stoter
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
British journal of cancer 1997;75(3):432-5.
1997: manon huizing; G Giaccone; LJ van Warmerdam; Hilde Rosing; P J M Bakker; Jan B Vermorken; P E Postmus; nico van zandwijk; M G Koolen; Wim W ten Bokkel Huinink; W J van der Vijgh; F J Bierhorst; A Lai; Otilia Dalesio; HERBERT PINEDO; Cindy Veenhof; Jos H Beijnen
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):317-29.
1996: Geert-Jan Creemers; Giorgio Bolis; M Gore; Giovanna Scarfone; A J Lacave; J P Guastalla; R Despax; G Favalli; R Kreinberg; S Van Belle; IR Hudson; Jaap Verweij; Wim W ten Bokkel Huinink
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(12):3056-61.
1996: Virginie M M Herben; Wim W ten Bokkel Huinink; Jos H Beijnen
Clinical pharmacokinetics of topotecan.
Clinical pharmacokinetics 1996;31(2):85-102.
1996: E M Davelaar; Johannes M G Bonfrer; Rob A Verstraeten; Wim W ten Bokkel Huinink; Peter Kenemans
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?
Cancer 1996;78(1):118-27.
1996: Richard Hoetelmans; Jan Schornagel; Wim W ten Bokkel Huinink; Jos H Beijnen
Hypersensitivity reactions to etoposide.
The Annals of pharmacotherapy 1996;30(4):367-71.
1996: Renato A Valdés Olmos; Wim W ten Bokkel Huinink; L G H Dewit; Cornelis A Hoefnagel; I H Liem; H van Tinteren
Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy.
European journal of nuclear medicine 1996;23(4):453-8.
1996: N K Aaronson; E Visser-Pol; G Leenhouts; Martin J Muller; A C van der Schot; Frits S A M van Dam; Ronald Bernard Keus; C C Koning; Wim W ten Bokkel Huinink; JA van Dongen; Ria Dubbelman
Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):984-96.
1996: LJ van Warmerdam; Geert-Jan Creemers; Sjoerd Rodenhuis; Hilde Rosing; MM de Boer-Dennert; J H M Schellens; Wim W ten Bokkel Huinink; brian e davies; R A Maes; Jaap Verweij; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: LJ van Warmerdam; Sjoerd Rodenhuis; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
Cancer chemotherapy and pharmacology 1996;37(3):266-70.
1995: R van Gijn; E Havik; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jos H Beijnen
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: LJ van Warmerdam; Olaf van Tellingen; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; R A Maes; J H Bijnen
Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?
Therapeutic drug monitoring 1995;17(5):465-70.
1995: manon huizing; Jan B Vermorken; Hilde Rosing; Wim W ten Bokkel Huinink; IA Mandjes; HERBERT PINEDO; Jos H Beijnen
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):699-704.
1995: Giuseppe Giaccone; manon huizing; P E Postmus; Wim W ten Bokkel Huinink; M Koolen; nico van zandwijk; Jan B Vermorken; Jos H Beijnen; Otilia Dalesio; HERBERT PINEDO
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):78-82.
1995: Jan B Vermorken; Wim W ten Bokkel Huinink; I A Mandjes; Tjeerd J Postma; manon huizing; J J Heimans; Jos H Beijnen; F Bierhorst; B Winograd; HERBERT PINEDO
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Seminars in oncology 1995;22(4 Suppl 8):16-22.
1995: LJ van Warmerdam; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; I Koier; brian e davies; Hilde Rosing; R A Maes; Jos H Beijnen
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1768-76.
1995: Wim W ten Bokkel Huinink; Cindy Veenhof; TJ Helmerhorst; F Bierhorst; Otilia Dalesio; B Winograd; L Depauw; HERBERT PINEDO
Paclitaxel plus carboplatin in the treatment of ovarian cancer.
Seminars in oncology 1995;22(3 Suppl 6):97-100.
1995: R de Wit; G Stoter; D T Sleijfer; Stanley B Kaye; P H M De Mulder; Wim W ten Bokkel Huinink; P J Spaander; M de Pauw; R Sylvester
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
British journal of cancer 1995;71(6):1311-4.
1995: R van Gijn; Olaf van Tellingen; J J de Clippeleir; Michel J X Hillebrand; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; S Schwertz; P Graf; Jos H Beijnen
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: M W Dercksen; K Hoekman; JJ Visser; Wim W ten Bokkel Huinink; HERBERT PINEDO; John Wagstaff
Hypotension induced by interleukin-3 in patients on angiotensin-converting enzyme inhibitors.
Lancet 1995;345(8947):448.
1995: A A Van Vliet; R Kröger; Ria Dubbelman; Wim W ten Bokkel Huinink
Treatment of patients with IVCS and gross oedema and ascites with diuretic combination and ACE-inhibitors: relation to baseline PRA and PAC.
The Netherlands journal of medicine 1995;46(2):62-72.
1995: Jan B Vermorken; A Kobierska; M E L van der Burg; B Chevallier; FLAVIA ZANABONI; Wim W ten Bokkel Huinink; M Forni; A Pawinski; E van der Putten; Giorgio Bolis
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.
European journal of gynaecological oncology 1995;16(6):433-8.
1995: Renato A Valdés Olmos; Wim W ten Bokkel Huinink; R F ten Hoeve; H van Tinteren; Peter Bruning; B van Vlies; Cornelis A Hoefnagel
Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy.
European journal of cancer (Oxford, England : 1990) 1995;31A(1):26-31.
1995: LJ van Warmerdam; Sjoerd Rodenhuis; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
The use of the Calvert formula to determine the optimal carboplatin dosage.
Journal of cancer research and clinical oncology 1995;121(8):478-86.
1995: manon huizing; V H Misser; R C Pieters; Wim W ten Bokkel Huinink; Cindy Veenhof; Jan B Vermorken; HERBERT PINEDO; J H Beijnen
Taxanes: a new class of antitumor agents.
Cancer investigation 1995;13(4):381-404.
1995: Sjoerd Rodenhuis; ELSKEN VAN DER WALL; Wim W ten Bokkel Huinink; Jan H Schornagel; Dick J Richel; L T Vlasveld
Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer.
Cancer investigation 1995;13(4):355-62.
1994: Elizabeth A Eisenhauer; Wim W ten Bokkel Huinink; kenneth d swenerton; Luca Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2654-66.
1994: Jos H Beijnen; manon huizing; Wim W ten Bokkel Huinink; Cindy Veenhof; Jan B Vermorken; Giuseppe Giaccone; HERBERT PINEDO
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Seminars in oncology 1994;21(5 Suppl 8):53-62.
1994: Giuseppe Giaccone; manon huizing; Wim W ten Bokkel Huinink; M Koolen; P Postmus; K van Kralingen; nico van zandwijk; Jan B Vermorken; Jos H Beijnen; Otilia Dalesio
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Seminars in oncology 1994;21(5 Suppl 8):34-8.
1994: Renato A Valdés Olmos; Wim W ten Bokkel Huinink; R F ten Hoeve; H van Tinteren; Peter Bruning; B van Vlies; Cornelis A Hoefnagel
Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(7):617-22.
1994: Wim W ten Bokkel Huinink; M W Dercksen; H van Tinteren
Further studies to ameliorate toxicity of carboplatin.
Seminars in oncology 1994;21(2 Suppl 2):27-33; quiz 34, 58.
1994: Amit Oza; Wim W ten Bokkel Huinink; Ria Dubbelman; O Soepenberg; IA Mandjes; E Aartsen; J G McVie
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):343-7.
1994: Wim W ten Bokkel Huinink; LJ van Warmerdam; A C Dubbelman; J G McVie; Jos H Beijnen
Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(2):133-9.
1994: H R Franklin; G P Simonetti; A C Dubbelman; Wim W ten Bokkel Huinink; Babs G Taal; G Wigbout; IA Mandjes; Otilia Dalesio; N K Aaronson
Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(2):113-7.
1994: LJ van Warmerdam; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
Limited-sampling models for anticancer agents.
Journal of cancer research and clinical oncology 1994;120(7):427-33.
1994: Babs G Taal; F G Teller; Wim W ten Bokkel Huinink; Henk Boot; Jos H Beijnen; Ria Dubbelman
Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(1):90-2.
1994: Jos H Beijnen; E M Bais; Wim W ten Bokkel Huinink
Lithium pharmacokinetics during cisplatin-based chemotherapy: a case report.
Cancer chemotherapy and pharmacology 1994;33(6):523-6.
1993: R van Gijn; S Kuijs; Hilde Rosing; A C Dubbelman; Olaf van Tellingen; Wim W ten Bokkel Huinink; HERBERT PINEDO; Jos H Beijnen
Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1993;11(11-12):1345-8.
1993: manon huizing; A C Keung; Hilde Rosing; V van der Kuij; Wim W ten Bokkel Huinink; IA Mandjes; A C Dubbelman; HERBERT PINEDO; Jos H Beijnen
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2127-35.
1993: M W Dercksen; K Hoekman; Wim W ten Bokkel Huinink; E M Rankin; Ria Dubbelman; H van Tinteren; John Wagstaff; HERBERT PINEDO
Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
British journal of cancer 1993;68(5):996-1003.
1993: Jos H Beijnen; Hilde Rosing; Wim W ten Bokkel Huinink; HERBERT PINEDO
High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma.
Journal of chromatography 1993;617(1):111-7.
1993: R van Gijn; Hilde Rosing; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jan B Vermorken; A J Liefting; R Bruno; HERBERT PINEDO; Jos H Beijnen
Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;614(2):299-306.
1993: E H Hopman; Theo J M Helmerhorst; Johannes M G Bonfrer; Wim W ten Bokkel Huinink
Highly elevated serum CA 125 levels in a patient with cardiac failure.
European journal of obstetrics, gynecology, and reproductive biology 1993;48(1):71-3.
1993: Babs G Taal; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis
Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(1):81-2.
1993: G Stoter; D Sleijfer; Stanley B Kaye; W G Jones; Wim W ten Bokkel Huinink; M de Pauw; R Sylvester
Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience.
European urology 1993;23(1):202-6.
1993: D G Allen; J Baak; D Belpomme; J S Berek; Kamma Bertelsen; Wim W ten Bokkel Huinink; M E L van der Burg; A H Calvert; P F Conte; J Dauplat
Advanced epithelial ovarian cancer: 1993 consensus statements.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():83-8.
1993: Jan B Vermorken; Wim W ten Bokkel Huinink; E A Eisenhauer; G Favalli; D Belpomme; P F Conte; S B Kaye
Advanced ovarian cancer. Carboplatin versus cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():41-8.
1993: Wim W ten Bokkel Huinink; Elizabeth Eisenhauer; K Swenerton
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.
Cancer treatment reviews 1993;19 Suppl C():79-86.
1992: Wim W ten Bokkel Huinink; M Clavel; Sjoerd Rodenhuis; J P Guastalla; H R Franklin; J J Koier; T Vlasveld; Otilia Dalesio; H van Tinteren; HERBERT PINEDO
Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer.
Pathologie-biologie 1992;39(9):962.
1992: Sjoerd Rodenhuis; L T Vlasveld; Ria Dubbelman; R Roodbergen; Jan H Schornagel; Jantien Wanders; S P Israels; E Bais; Wim W ten Bokkel Huinink; Dick J Richel
Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(6):463-7.
1992: Jos H Beijnen; L T Vlasveld; Jantien Wanders; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis
Effect of cisplatin-containing chemotherapy on lithium serum concentrations.
The Annals of pharmacotherapy 1992;26(4):488-90.
1992: Renato A Valdés Olmos; Wim W ten Bokkel Huinink; J C Greve; Cornelis A Hoefnagel
I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity.
Clinical nuclear medicine 1992;17(3):163-7.
1992: Olaf van Tellingen; Jos H Beijnen; R Baurain; Wim W ten Bokkel Huinink; H R van der Woude; W J Nooyen
Biodetermination of N-(deacetyl-O-4-vinblastoyl-23)-L-tryptophan, a metabolite of vintriptol, by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1992;574(2):293-8.
1992: Wim W ten Bokkel Huinink; Otilia Dalesio; Sjoerd Rodenhuis; Ria Dubbelman; A Hilton; H Franklin; I Koier; H van Tinteren; M E L van der Burg; AT van Oosterom
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
Seminars in oncology 1992;19(1 Suppl 2):99-101.
1992: B C Tanis; Jan B Vermorken; Wim W ten Bokkel Huinink; AT van Oosterom; T A Splinter; K J Vendrik; D T Sleijfer; M E L van der Burg; E van der Putten; HERBERT PINEDO
Multicenter phase II study of spiroplatin.
Oncology 1992;49(2):99-103.
1991: Olaf van Tellingen; Jos H Beijnen; R Baurain; Wim W ten Bokkel Huinink; H R van der Woude; W J Nooyen
High-performance liquid chromatographic determination of vinblastine, 4-O-deacetylvinblastine and the potential metabolite 4-O-deacetylvinblastine-3-oic acid in biological fluids.
Journal of chromatography 1991;553(1-2):47-53.
1991: V Lustig; L T Vlasveld; R H Bakker; J E Schreuder; W J Mooi; Wim W ten Bokkel Huinink
Intracardiac metastases, report of three cases.
The Netherlands journal of medicine 1991;38(1-2):29-32.
1991: J P Neijt; Wim W ten Bokkel Huinink; M E L van der Burg; AT van Oosterom; P H Willemse; J B Vermorken; A C van Lindert; A Peter M Heintz; E Aartsen; M van Lent
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
European journal of cancer (Oxford, England : 1990) 1991;27(11):1367-72.
1991: H M Oosterkamp; L T Vlasveld; Jantien Wanders; Jos H Beijnen; Olaf van Tellingen; A C Dubbelman; G P Simonetti; H R Franklin; Jan B Vermorken; Wim W ten Bokkel Huinink
Phase I study of vintriptol, a tryptophan ester of vinblastine.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1222-6.
1991: R L Jansen; R Sylvester; D T Sleyfer; Wim W ten Bokkel Huinink; Stanley B Kaye; W G Jones; J Keizer; AT van Oosterom; S Meyer; C P Vendrik
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)
European journal of cancer (Oxford, England : 1990) 1991;27(6):695-8.
1991: B C Tanis; Jan B Vermorken; Wim W ten Bokkel Huinink; I Klein; H Gall; A T van Oosterom; G Simonetti; J G McVie; Wim J F van der Vijgh; HERBERT PINEDO
Phase I study of spiroplatin.
European journal of cancer (Oxford, England : 1990) 1991;27(3):268-73.
1990: Willem Boogerd; Wim W ten Bokkel Huinink; Otilia Dalesio; W J Hoppenbrouwers; JJ van der Sande
Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.
Journal of neuro-oncology 1990;9(3):255-63.
1990: L T Vlasveld; Wim W ten Bokkel Huinink; S Rodenhuis
Neutropenic enterocolitis in a patient with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor (GM-CSF).
The Netherlands journal of medicine 1990;37(3-4):158-61.
1990: Olaf van Tellingen; H R van der Woude; Jos H Beijnen; K S Rao; Wim W ten Bokkel Huinink; W J Nooyen
High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol.
Journal of chromatography 1990;529(2):329-38.
1990: nico van zandwijk; Wim W ten Bokkel Huinink; Jantien Wanders; G Simonetti; Ria Dubbelman; H Franklin; H van Tinteren; J G McVie
Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.
Seminars in oncology 1990;17(1 Suppl 2):16-9.
1990: A Koopman; C P Vendrik; D T Sleyfer; AT van Oosterom; Wim W ten Bokkel Huinink; G Stoter
[Cured of testicular cancer; does life just go on?].
Nederlands tijdschrift voor geneeskunde 1990;134(1):23-5.
1990: L T Vlasveld; J H Beynen; Willem Boogerd; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis
Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.
Cancer chemotherapy and pharmacology 1990;25(5):382-3.
1990: Gilberto Schwartsmann; P Dodion; Jan B Vermorken; Wim W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; Wim J F van der Vijgh; M B van Hennik
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Cancer chemotherapy and pharmacology 1990;25(5):345-51.
1990: Jos H Beijnen; B R Smith; W J Keijer; R van Gijn; Wim W ten Bokkel Huinink; L T Vlasveld; Sjoerd Rodenhuis; Willy J M Underberg
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):789-94.
1990: Olaf van Tellingen; Jos H Beijnen; H R van der Woude; R Baurain; Wim W ten Bokkel Huinink; W J Nooyen
Bio-analysis of N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate, methane sulphonate (VileE) by high-performance liquid chromatography with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):1029-31.
1989: Gilberto Schwartsmann; Wim J F van der Vijgh; M B van Hennik; I Klein; Jan B Vermorken; P Dodion; Wim W ten Bokkel Huinink; G Joggi; H Gall; N Crespeigne
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
European journal of cancer & clinical oncology 1989;25(12):1675-81.
1989: G Stoter; A Koopman; C P Vendrik; A Struyvenberg; D T Sleyfer; P H Willemse; H Schraffordt Koops; AT van Oosterom; Wim W ten Bokkel Huinink; HERBERT PINEDO
Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1099-104.
1989: Gilberto Schwartsmann; E Bork; Jan B Vermorken; C Nieboer; P Dodion; Wim W ten Bokkel Huinink; C A Seldenrijk; J P Armand; HERBERT PINEDO
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Cancer 1989;63(2):243-8.
1988: Wim W ten Bokkel Huinink; M E L van der Burg; AT van Oosterom; J P Neijt; M George; J P Guastalla; Cindy Veenhof; N Rotmensz; Otilia Dalesio; Jan B Vermorken
Carboplatin in combination therapy for ovarian cancer.
Cancer treatment reviews 1988;15 Suppl B():9-15.
1988: Wim J F van der Vijgh; F Elferink; Jan B Vermorken; Wim W ten Bokkel Huinink; I Klein; H E Gall; G Simonetti; J G McVie; HERBERT PINEDO
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
European journal of cancer & clinical oncology 1988;24(4):621-7.
1988: P W de Graaf; M M Mellema; Wim W ten Bokkel Huinink; E J Aartsen; Ria Dubbelman; H R Franklin; Augustinus A M Hart
Complications of Tenckhoff catheter implantation in patients with multiple previous intraabdominal procedures for ovarian carcinoma.
Gynecologic oncology 1988;29(1):43-9.
1988: F Elferink; Wim J F van der Vijgh; I Klein; Wim W ten Bokkel Huinink; Ria Dubbelman; J G McVie
Pharmacokinetics of carboplatin after intraperitoneal administration.
Cancer chemotherapy and pharmacology 1988;21(1):57-60.
1988: G Stoter; R Sylvester; D T Sleijfer; Wim W ten Bokkel Huinink; Stanley B Kaye; W G Jones; AT van Oosterom; C P Vendrik; P Spaander; M de Pauw
A multivariate analysis of prognostic factors in disseminated non-seminomatous testicular cancer.
Progress in clinical and biological research 1988;269():381-93.
1987: F Elferink; Wim J F van der Vijgh; Wim W ten Bokkel Huinink; Jan B Vermorken; I Klein; B Winograd; M Tish Knobf; G Simonetti; H E Gall; J G McVie
Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
British journal of cancer 1987;56(4):479-83.
1987: J P Neijt; Wim W ten Bokkel Huinink; M E L van der Burg; AT van Oosterom; P H Willemse; A Peter M Heintz; M van Lent; J Baptist Trimbos; J Bouma; J B Vermorken
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(8):1157-68.
1987: M E L van der Burg; Wim W ten Bokkel Huinink; R Vriesendorp; AT van Oosterom; J P Neijt; Jan B Vermorken; Wim L J van Putten; A Kooiman
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
European journal of cancer & clinical oncology 1987;23(7):997-8.
1987: M George; V Scotto; Flavio Carnino; P Dodion; Wim W ten Bokkel Huinink; N Rotmensz; Jan B Vermorken
Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.
European journal of cancer & clinical oncology 1987;23(6):867-9.
1987: G Stoter; R Sylvester; D T Sleijfer; Wim W ten Bokkel Huinink; Stanley B Kaye; W G Jones; AT van Oosterom; C P Vendrik; P Spaander; M de Pauw
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study.
Cancer research 1987;47(10):2714-8.
1987: P W de Graaf; Wim W ten Bokkel Huinink; E J Aartsen; M M Mellema; Ria Dubbelman; A A Hart
[Complications following implantatation of a Tenckhoff catheter for the intraperitoneal administration of chemotherapeutic agents].
Nederlands tijdschrift voor geneeskunde 1987;131(8):323-6.
1987: G Stoter; R Sylvester; D T Sleijfer; Wim W ten Bokkel Huinink; Stanley B Kaye; W G Jones; AT van Oosterom; C P Vendrik; P Spaander; M De Pauw
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III study.
International journal of andrology 1987;10(1):239-46.
1986: G Stoter; D T Sleyfer; Wim W ten Bokkel Huinink; Stanley B Kaye; W G Jones; AT van Oosterom; C P Vendrik; P Spaander; M de Pauw; R Sylvester
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(8):1199-206.
1986: B Winograd; Jan B Vermorken; Wim W ten Bokkel Huinink; G Simonetti; H E Gall; M Tish Knobf; Wim J F van der Vijgh; J G McVie; HERBERT PINEDO
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Cancer research 1986;46(4 Pt 2):2148-51.
1985: Wim W ten Bokkel Huinink; Ria Dubbelman; E Aartsen; H Franklin; J G McVie
Experimental and clinical results with intraperitoneal cisplatin.
Seminars in oncology 1985;12(3 Suppl 4):43-6.
1984: G Stoter; C P Vendrik; A Struyvenberg; D T Sleyfer; R Vriesendorp; H Schraffordt Koops; AT van Oosterom; Wim W ten Bokkel Huinink; HERBERT PINEDO
Five-year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin.
Cancer 1984;54(8):1521-4.
1984: J P Neijt; Wim W ten Bokkel Huinink; M E L van der Burg; AT van Oosterom; R Vriesendorp; C D Kooyman; A C van Lindert; J V Hamerlynck; M van Lent; J C van Houwelingen
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Lancet 1984;2(8403):594-600.
1984: J P Neijt; Wim W ten Bokkel Huinink; M E L van der Burg; AT van Oosterom; R Vriesendorp; HERBERT PINEDO
Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1984;2(1):19-29.